Coronado Biosciences Reports Financial Results for the Fourth Quarter and Year Ended

Coronado Biosciences Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2011

Burlington, MA March 29, 2012 Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of

autoimmune diseases and cancer, today announced its financial results for the fourth quarter and year ended December 31, 2011.

reported a net loss of $6.7 million, or $0.52 per share, for the fourth quarter of 2011 compared to a net loss of $1.6 million, or $0.34 per share, for the fourth quarter of 2010. For the year ended December 31, 2011, Coronado reported a net

loss, before the common stock dividend to the Series A Preferred Stockholders, of $36.4 million, or $4.74 per share, compared to a net loss of $10.0 million, or $2.24 per share, for 2010. Included in the net loss for 2011 was in-process research and

development expense of $20.7 million in connection with the acquisition of the TSO (Trichuris suis ova or CNDO-201) related assets.

Research and development expenses were $8.6 million for the year ended December 31, 2011, compared to $8.3 million for 2010. General and

administrative expenses totaled $5.8 million for the year ended December 31, 2011, compared to $0.9 million for 2010. In 2011, R&D included expenses related to the TSO clinical program and G&A included expenses related to the

company s infrastructure growth, increased business activity and becoming a publicly-traded entity. At December 31, 2011, Coronado s cash and cash equivalents totaled $23.2 million.

2011 was a very important year for Coronado, where we made tremendous progress in building the company and advancing our clinical stage

programs, said Dr. Bobby W. Sandage, Jr., President and Chief Executive Officer. We successfully consolidated two exciting clinical stage programs into the company, transitioned from a private company to a NASDAQ-listed

company, built an outstanding management team, and most importantly advanced our first-in-class programs for autoimmune diseases and cancer into further clinical development.

We are committed to continuing our momentum throughout 2012 and beyond as we initiate our Phase 2b clinical trial of TSO in Crohn s disease in the second quarter of this year, in addition to

looking forward to the progress of the Phase 2 trial being conducted in Europe by our development partner, Dr. Falk Pharma GmbH (Falk), Dr. Sandage continued. We believe additional successful studies for TSO will further

validate our approach of using this novel biologic to treat a number of other autoimmune diseases. For our CNDO-109 program, we plan to initiate our Phase 1/2 trial in mid-2012, leveraging the successful Phase 1 data generated in patients with Acute

Myeloid Leukemia (AML) which was presented late last year at the American Society of Hematology conference.

Recent Scientific Highlights:

Conference Call and Webcast Information

Coronado management will review its fourth quarter and year-end financial results and development programs via conference call and webcast today at 8:30

a.m. Eastern Time. To participate in the conference call, please dial 877-312-5413 (toll free from the US and Canada), or 253-237-1511 (for international callers). Investors may also access a live audio webcast of the call at

www.coronadobiosciences.com on the Events & Webcasts page.

A replay of the webcast will be available shortly after the

conclusion of the call. The webcast archive will remain available for one year. An audio replay will also be available shortly after the conclusion of the call and will be made available until April 5, 2012. The audio replay can be accessed by

dialing 855-859-2056 (toll free from the US and Canada), or 404-537-3406 (for international callers) and entering Event ID 63672182.

Coronado Biosciences

Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The company s

two principal pharmaceutical product candidates in clinical development are: TSO (Trichuris suis ova or CNDO-201), a biologic for the treatment of autoimmune diseases, such as Crohn s disease, ulcerative colitis and multiple sclerosis;

and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML) and solid tumors. For more information, please visit www.coronadobiosciences.com.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such

statements include, but are not limited to, any statements relating to the company s product development programs and any other statements that are not historical facts. Forward-looking statements are based on management s current

expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated

risks relating to the results of research and development activities, uncertainties relating to preclinical and clinical testing, financing and strategic agreements and relationships, the early stage of products under development, our need for

substantial additional funds, government regulation, patent and intellectual property matters; our dependence on third party suppliers and competition, as well as other risks described in our SEC filings. We expressly disclaim any obligation or

undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except

Contact Information:

Lucy Lu, MD, Executive Vice President & Chief Financial

Coronado Biosciences, Inc.

781-238-6619; ir@coronadobio.com

The Trout Group, LLC.

646-378-2927; mnanus@troutgroup.com

Dennis S. Dobson Jr., CEO

203-258-0159; dobsonpr@erols.com

CORONADO BIOSCIENCES, INC. AND SUBSIDIARY

(A development stage enterprise)

Consolidated Balance Sheets

($ in thousands except for share amounts)

CORONADO BIOSCIENCES, INC. AND SUBSIDIARY

(A development stage enterprise)

Consolidated Statements of Operations

($ in thousands except for share

and per share amounts)